• Tracking the evolving landscape of cell therapy treatments: new modalities and indications
• Next generation platforms and innovative clinical studies unlock potential of allogeneic therapies
• Reducing variability, improving success rates improves cost, access, and scale
• How manufacturing and operations enables clinical execution in a dynamic regulatory environment